Evidence map›Paper›PMID 28383559›Full record

ArticleCell death & disease2017

Erythropoietin protects against rhabdomyolysis-induced acute kidney injury by modulating macrophage polarization.

Shuo Wang, Chao Zhang, Jiawei Li, Sidikejiang Niyazi, Long Zheng, Ming Xu, Ruiming Rong, Cheng Yang, Tongyu Zhu

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 1 pooled it
7.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 1 synthesis or guideline pooled it, 87 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Decades Long Involvement of THP-1 Cells as a Model for Macrophage Research: A Comprehensive Review.Anti-inflammatory & anti-allergy agents in medicinal chemistry · 2024
    Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Shuo WangDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Chao ZhangDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID 0000-0001-9672-0720
Jiawei LiDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Sidikejiang NiyaziDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Long ZhengDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Ming XuDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Ruiming RongDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Cheng YangDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Tongyu ZhuDepartment of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
Sun Yat-sen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Erythropoietin (EPO) is a well-known hormone that is clinically used for the treatment of anemia. Very recently, an increasing body of evidence showed that EPO could still regulate bioactivities of macrophages. However, the details about the immunomodulatory effect of EPO on macrophages are not fully delineated, particularly in the setting of renal damages. Therefore, in the present study, we determined whether EPO could exert an impact on the dynamics of macrophages in a well-established model of rhabdomyolysis-induced acute kidney injury and explored the potential mechanisms. EPO was found to ameliorate kidney injuries by reducing macrophages recruitment and promoting phenotype switch toward M2 macrophages in vivo. It was also confirmed that EPO could directly suppress pro-inflammatory responses of M1 macrophages and promote M2 marker expression in vitro. Data indicated the possible involvement of Jak2/STAT3/STAT6 pathway in the augmentation of EPO on M2 polarization. These results improved the understanding of the immunoregulatory capacity of EPO on macrophages, which might optimize the therapeutic modalities of EPO.

Indexed as

Acute Kidney InjuryAnimalsErythropoietinJanus Kinase 2MacrophagesMiceRhabdomyolysisSignal TransductionSTAT3 Transcription FactorSTAT6 Transcription FactorErythropoietinJak2 protein, mouseJanus Kinase 2Stat3 protein, mouseSTAT3 Transcription FactorStat6 protein, mouseSTAT6 Transcription Factor

Identifiers

PMID28383559
PMCPMC5477572
OpenAlexW2604507726

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.